Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
N. Zanaletti
Observed names:
Nicoletta Zanaletti,
Zanaletti N.,
Zanaletti, Nicoletta
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
University of Campania "Luigi Vanvitelli",
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
INCLIVA Health Research Institute
ORCID:
0000-0002-2675-2396
Observed ORCID:
0000-0002-2675-2396
OpenAlex ID:
A5050411971
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial
2021
·
Erika Martinelli
, Giulia Martini
, et al.
·
JAMA Oncology
·
199
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
2023
·
Joris van de Haar
, Xuhui Ma
, et al.
·
Nature Medicine
·
96
PDF
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
2019
·
Pietro Paolo Vitiello
, Vincenzo De Falco
, et al.
·
Cancers
·
61
PDF
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients
2020
·
Emilio Francesco Giunta
, Giusi Barra
, et al.
·
Scientific Reports
·
43
PDF
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials
2022
·
Emiliano Tamburini
, Davide Tassinari
, et al.
·
Critical Reviews in Oncology/Hematology
·
34
491P Neoadjuvant nivolumab in early stage colorectal cancer
2020
·
A. Avallone
, A. De Stefano
, et al.
·
Annals of Oncology
·
34
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
2020
·
Vincenzo De Falco
, Luca Poliero
, et al.
·
ESMO Open
·
25
PDF
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
2021
·
Pasquale Vitale
, Nicoletta Zanaletti
, et al.
·
Clinical Colorectal Cancer
·
23
PDF
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
2020
·
Alessandro Parisi
, Alessio Cortellini
, et al.
·
Cancers
·
22
PDF
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis
2021
·
Maria Antonietta Isgrò
, Maria Grazia Vitale
, et al.
·
Journal of Translational Medicine
·
21
PDF
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature
2019
·
Giuseppe Viscardi
, Nicoletta Zanaletti
, et al.
·
ESMO Open
·
18
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme
2017
·
Vincenzo Sforza
, Erika Martinelli
, et al.
·
ESMO Open
·
17
Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
2021
·
Alessandro Ottaiano
, Stefania Scala
, et al.
·
Therapeutic Advances in Medical Oncology
·
14
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
2019
·
Vincenzo De Falco
, Maria Iole Natalicchio
, et al.
·
Medicine
·
14
Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
2021
·
Alessandro Parisi
, Giampiero Porzio
, et al.
·
Clinical Colorectal Cancer
·
12
Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
2019
·
Teresa Troiani
, Erika Martinelli
, et al.
·
Journal of Clinical Oncology
·
10
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study
2023
·
C. Cardone
, A. De Stefano
, et al.
·
ESMO Open
·
8
Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review.
2019
·
Alfonso Reginelli
, Giovanna Vacca
, et al.
·
Acta bio-medica dell'Ateneo parmense/Acta biomedica
·
8
PDF
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
2021
·
Alessandro Parisi
, Alessio Cortellini
, et al.
·
Frontiers in Oncology
·
6
PDF
13P Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status
2020
·
E.F. Giunta
, V. Belli
, et al.
·
Annals of Oncology
·
6
PDF
Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon
2019
·
E. Martinelli
, T. Troiani
, et al.
·
Annals of Oncology
·
6
PDF
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
2021
·
Paolo Antonetti
, Maria Concetta Fargnoli
, et al.
·
Supportive Care in Cancer
·
4
AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
2018
·
C. Cardone
, B. Blauensteiner
, et al.
·
Annals of Oncology
·
4
Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report
2023
·
Alfonso De Stefano
, Nicoletta Zanaletti
, et al.
·
Frontiers in Oncology
·
3
PDF
GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
2019
·
P.P. Vitiello
, L. Mele
, et al.
·
Annals of Oncology
·
3
Show more works
View as search
Works count:
61
Citation count:
701
H-index:
14
I10-index:
16
Year
Topic
Type